2 completed. 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 2 |
| Phase 2 | 1 | Completed 1 |
Follow Excessive Daytime Somnolence: new trials by email Literature Review of Excessive Daytime Somnolence trials Research Report on Excessive Daytime Somnolence
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Open Label Study of FT218 in Subjects With Narcolepsy FT218 - Narcolepsy, Cataplexy | Phase 3 | Completed | Avadel | 184 | 2020-06-12 | 2025-10-02 |
| Caffeine for Excessive Daytime Somnolence in Parkinson's Disease Caffeine 100-200 mg BID, placebo - Parkinson's Disease, Excessive Daytime Somnolence | Phase 2 / Phase 3 | Completed | Ron Postuma | 58 | 2007-04-01 | 2015-04-16 |
Disorders of Excessive Somnolence (2) · Cataplexy (1) · Narcolepsy (1) · Parasomnias (1) · Parkinson Disease (1) · Sleep Wake Disorders (1)
Dyssomnias (2) · Mental Disorders (2) · Nervous System Diseases (2) · Sleep Disorders, Intrinsic (2) · Basal Ganglia Diseases (1) · Brain Diseases (1) · Central Nervous System Diseases (1) · Movement Disorders (1) · Neurodegenerative Diseases (1) · Neurologic Manifestations (1) · Parkinsonian Disorders (1) · Pathological Conditions, Signs and Symptoms (1) · Signs and Symptoms (1) · Sleep Wake Disorders (1) · Synucleinopathies (1)
BID protein, human (1) · Caffeine (1)
Avadel (1) · Ron Postuma (1)
Canada (2) · United States (1)